Drugs / ARN-75039
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06911242 | Feb → Apr 2025 | — | Arisan Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05735249 | Jan 2023 → Mar 2025 | — | Arisan Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07419373 | Feb 2026 → Jun 2027 | Lassa fever | Arisan Therapeutics, Inc. | Suspended | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06212336 | May 2025 → Jun 2027 expected | Lassa fever | Irrua Specialist Teaching Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARN-75039 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06911242 ↗ |
| Action | Inhibit | “inhibits viral entry by targeting the Lassa virus glycoprotein complex” NCT07419373 ↗ |
| Modality | Small molecule | “small-molecule antiviral” NCT07419373 ↗ |
| Route | Oral | “active oral study drug prepared and administered as oral capsules” NCT05735249 ↗ |